Johnson & Johnson’s COVID-19 vaccine helps protect against moderate to severe illness, newly published clinical trial results show. The jab was 67 percent effective in protecting against moderate to severe COVID-19, the disease caused by the CCP (Chinese Communist Party) virus, at 14 days after vaccination, according to research published in the New England Journal of Medicine. Researchers also found that there was 66 percent efficacy at 28 days post-vaccination and prevention against hospitalization and death across all 44,325 participants. Johnson & Johnson’s shot was authorized for emergency use in February but is currently on pause because of cases where people who were vaccinated developed blood clots in combination with low blood platelet levels, even as the United States battles a variety of virus variants. Variants in the ongoing clinical trial, known as the ENSEMBLE study, included the so-called South African variant and a variant believed to have originated in Brazil. …